Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imsidolimab Long-Term Safety and Efficacy in GPP (Extension of ANB019-301)
CTR20230709Phase 3Terminated
- Sponsor
- AnaptysBio, Inc.
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of imsidolimab in generalized pustular psoriasis (GPP), sponsored by AnaptysBio, Inc.. Started Mar 2023; status: terminated.
02
Drugs
imsidolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on CTR20230709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230709.